A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
Price : $35 *
At a glance
- Drugs Ruxolitinib (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Incyte Corporation
- 09 Jun 2017 Status changed from active, no longer recruiting to discontinued.
- 19 Dec 2016 This trial has been completed in Portugal (end date: 21 Jun 2016).
- 27 Aug 2016 This trial was completed in Italy (end date: 21 Jun 2016).